Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0,47%
1 067,36
+4,96
+0,47%
—1 062,401 064,141 071,991 061,02——
SIXC
Communications
SIXC
Communications
SIXC
-0,54%
603,48
-3,26
-0,54%
—606,74606,74609,84602,33——
SIXE
Energy
SIXE
Energy
SIXE
+0,54%
1 244,93
+6,72
+0,54%
—1 238,211 236,601 247,741 232,10——
SIXI
Industrials
SIXI
Industrials
SIXI
+0,68%
1 730,38
+11,77
+0,68%
—1 718,611 723,231 741,481 717,47——
SIXM
Financials
SIXM
Financials
SIXM
+0,33%
639,47
+2,10
+0,33%
—637,37638,27642,30638,27——
SIXR
Staples
SIXR
Staples
SIXR
+0,16%
854,95
+1,36
+0,16%
—853,59854,05858,19851,34——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0,11%
218,56
+0,23
+0,11%
—218,33218,33219,73217,15——
SIXT
Technology
SIXT
Technology
SIXT
+1,02%
3 631,59
+36,78
+1,02%
—3 594,813 620,103 657,473 615,34——
SIXU
Utilities
SIXU
Utilities
SIXU
+0,80%
915,77
+7,23
+0,80%
—908,54909,50917,35907,07——
SIXV
Health care
SIXV
Health care
SIXV
+1,19%
1 512,81
+17,81
+1,19%
—1 495,001 499,611 517,101 499,61——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,41%
2 408,21
+9,90
+0,41%
—2 398,312 406,822 421,802 404,22——
4516:TYO
Nippon Shinyaku Co Ltd
4 209,00 JP¥
-1,27%
(-54,00) 1D
22-май, 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4516...
Open
4 242 JP¥
High
4 280 JP¥
Low
4 189 JP¥
Mkt. cap
295,69 млд
Avg. vol.
234,75 миң
Volume
193,30 миң
Dividend
2,95%
Quarterly dividend
31 JP¥
Ex-dividend date
2026-ж., 30-мар.
P/E ratio
9,54
52-wk high
6 529 JP¥
52-wk low
2 967 JP¥
EPS
441 JP¥
Shares outstanding
67,35 млн
No. of employees
2 миң
News stories
From sources across the web
Profile
Nippon Shinyaku Co., Ltd. is a Japanese pharmaceutical company headquartered in Kyoto that develops, manufactures, and markets prescription drugs and functional foods. Founded in 1911, the company initially focused on herbal medicines before expanding into modern pharmaceuticals, with current therapeutic areas including urology, hematology, intractable and rare diseases, and gynecology. Nippon Shinyaku is listed on the Tokyo Stock Exchange and has developed treatments such as viltolarsen for Duchenne muscular dystrophy. Wikipedia
About Nippon Shinyaku Co Ltd
CEO-
Employees2,24 миң
Founded1919-ж., 1-окт.
Headquarters-
SectorPharmaceutical industry
Websitenippon-shinyaku.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
Revenue
39,55 млд
40,10 млд
47,49 млд
43,64 млд
Cost of goods sold
12,66 млд
12,68 млд
16,68 млд
15,45 млд
Cost of revenue
12,66 млд
12,68 млд
16,68 млд
15,45 млд
Research and development expenses
6,19 млд
8,45 млд
8,40 млд
13,68 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10,00 млд
10,36 млд
11,35 млд
11,86 млд
Operating expense
16,81 млд
17,92 млд
18,06 млд
25,02 млд
Total operating expenses
29,46 млд
30,60 млд
34,73 млд
40,47 млд
Operating income
10,08 млд
9,50 млд
12,75 млд
3,16 млд
Other non operating income
-2,00 млн
1,00 млн
-2,00 млн
1,00 млн
EBT including unusual items
10,50 млд
9,53 млд
13,20 млд
3,24 млд
EBT excluding unusual items
10,50 млд
9,53 млд
13,20 млд
3,24 млд
Income tax expense
2,25 млд
2,02 млд
3,11 млд
-642,00 млн
Effective tax rate
21,40%
21,19%
23,57%
-19,83%
Other operating expenses
625,00 млн
-888,00 млн
-1,68 млд
-518,00 млн
Net income
8,26 млд
7,50 млд
10,08 млд
3,88 млд
Net profit margin
20,87%
18,72%
21,23%
8,88%
Earnings per share
-
-
-
-
Interest and investment income
468,00 млн
82,00 млн
464,00 млн
118,00 млн
Interest expense
-46,00 млн
-55,00 млн
-19,00 млн
-46,00 млн
Net interest expenses
422,00 млн
27,00 млн
445,00 млн
72,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
11,67 млд
11,14 млд
14,41 млд
4,90 млд
Gain or loss from assets sale
-
19,00 млн
56,00 млн
56,00 млн
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer